In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness

Caecilia Schmid, Andrea Kuemmerle, Johannes Blum, Salah Ghabri, Victor Kande, Wilfried Mutombo, Medard Ilunga, Ismael Lumpungu, Sylvain Mutanda, Pathou Nganzobo, Digas Tete, Nono Mubwa, Mays Kisala, Severine Blesson, Olaf Valverde Mordt, Caecilia Schmid, Andrea Kuemmerle, Johannes Blum, Salah Ghabri, Victor Kande, Wilfried Mutombo, Medard Ilunga, Ismael Lumpungu, Sylvain Mutanda, Pathou Nganzobo, Digas Tete, Nono Mubwa, Mays Kisala, Severine Blesson, Olaf Valverde Mordt

Abstract

Background: Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and insufficiently effective in certain areas (melarsoprol). Recently, nifurtimox-eflornithine combination therapy (NECT) demonstrated good safety and efficacy in a randomised controlled trial (RCT) and was added to the World Health Organisation (WHO) essential medicines list (EML). Documentation of its safety profile in field conditions will support its wider use.

Methodology: In a multicentre, open label, single arm, phase IIIb study of the use of NECT for 2(nd) stage T.b. gambiense HAT, all patients admitted to the trial centres who fulfilled inclusion criteria were treated with NECT. The primary outcome was the proportion of patients discharged alive from hospital. Safety was further assessed based on treatment emergent adverse events (AEs) occurring during hospitalisation.

Principal findings: 629 patients were treated in six HAT treatment facilities in the Democratic Republic of the Congo (DRC), including 100 children under 12, 14 pregnant and 33 breastfeeding women. The proportion of patients discharged alive after treatment completion was 98.4% (619/629; 95%CI [97.1%; 99.1%]). Of the 10 patients who died during hospitalisation, 8 presented in a bad or very bad health condition at baseline; one death was assessed as unlikely related to treatment. No major or unexpected safety concerns arose in any patient group. Most common AEs were gastro-intestinal (61%), general (46%), nervous system (mostly central; 34%) and metabolic disorders (26%). The overall safety profile was similar to previously published findings.

Conclusions/significance: In field conditions and in a wider population, including children, NECT displayed a similar tolerability profile to that described in more stringent clinical trial conditions. The in-hospital safety was comparable to published results, and long term efficacy will be confirmed after 24 months follow-up.

Registration: The trial is registered at ClinicalTrials.gov, number NCT00906880.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Flow diagram of the multicentre…
Figure 1. Flow diagram of the multicentre NECT trial for treatment of 2nd stage HAT.
The diagram includes detailed information on excluded patients.

References

    1. WHO (2011) Neglected Tropical Diseases. Available: . Accessed 2012 Feb 20.
    1. Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, et al. (2010) The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr 9: 57.
    1. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, et al. (2005) Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: Confirmation from a multinational study (Impamel II). Journal of Infectious Diseases 191: 1922–1931.
    1. Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud ME, et al. (2009) Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans R Soc Trop Med Hyg 103: 280–290.
    1. Dahl B (2011) From sentinel surveillance for sleeping sickness treatment failure to the development of a pharmacovigilance approach [PhD thesis]. Basel: University of Basel. 149 p.
    1. Robays J, Nyamowala G, Sese C, Betu Ku Mesu Kande V, Lutumba P, et al. (2008) High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis 14: 966–967.
    1. Pepin J, Mpia B (2005) Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982–2001. Emerg Infect Dis 11: 921–927.
    1. Matovu E, Enyaru JC, Legros D, Schmid C, Seebeck T, et al. (2001) Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop Med Int Health 6: 407–411.
    1. Stanghellini A, Josenando T (2001) The situation of sleeping sickness in Angola: a calamity. Tropical Medicine and International Health 6: 330–334.
    1. WHO (2010) WHO Model List of Essential Medicines Available: . Accessed 2012 Feb 20.
    1. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374: 56–64.
    1. Program CTE (2006) Common Terminology Criteria for Adverse Events, Version 3.0 Available: . Accessed 2012 Feb 20.
    1. Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA (2005) Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 41: 748–751.
    1. Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, et al. (2008) Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 336: 705–708.
    1. Fleiss JL, Levin B, Paik MC (2003) Statistical Methods for Rates and Proportions. New York: John Wiley & Sons.
    1. NCSS (2008) PASS 2008 () accessed (20.02.2012).
    1. MEDRA (2010) Medical Dictionary for regulatory activities - Maintenance and Service Support Organisation. Available: . Accessed 2012 Feb 20.
    1. WHO (2006) ATC/DDD Index () accessed (20.02.2012)
    1. WHO (1995) Physical status: The use and interpretation of anthropometry () Accessed 2012 Feb 20.
    1. WHO (2007) Growth reference data for 5–19 years. Available: . Accessed 2012 Feb 20.
    1. Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, et al. (2006) Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 1: e39.
    1. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, et al. (2007) Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series. PLoS Negl Trop Dis 1: e64.
    1. Blum J, Schmid C, Burri C (2006) Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 97: 55–64.
    1. Blum JA, Schmid C, Burri C, Hatz C, Olson C, et al. (2009) Cardiac Alterations in Human African Trypanosomiasis (T.b. gambiense) with Respect to the Disease Stage and Antiparasitic Treatment. PLoS Negl Trop Dis 3: e383.
    1. Blum J, Nkunku S, Burri C (2001) Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 6: 390–400.
    1. Burri C, Nkunku S, Merolle A, Smith T, Blum J, et al. (2000) Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355: 1419–1425.
    1. Seixas J (2005) Investigations on the encephalopathic syndrome during melarsoprol treatment of human african trypanosomiasis [PhD]. Lisboa: Universidade Nova de Lisboa. 250 p.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться